Presentation

Presentation

Organizing Commission

In view of the recent developments in the field of arterial hypertension with the publication of several important studies which have changed the fundamental aspects of the daily practice of treating this disease, the publication in 1998 of IV Diretrizes Brasileiras de Hipertensão (IV Brazilian Guidelines on Hypertension) is extremely relevant.

The purpose of this paper, as well as that of the previous ones,¹–³, is to offer the medical community a practical, objective and appropriate guide to the Brazilian reality, to be used as a reference in the prevention, diagnosis, treatment and control of hypertension. The grade of recommendation based on the level of evidence has been used for the first time, in accordance with the rules of the Brazilian Medical Association. Two new chapters have also been added, namely Epidemiology and Secondary Hypertension, which have made the scope of this paper more comprehensive.

This paper was developed with the participation of 108 specialists from various areas in the country, and it was sponsored by the Brazilian Society of Hypertension, Brazilian Society of Cardiology, and Brazilian Society of Nephrology, in Campos do Jordão from February 1 - 3, 2002. Other participants included representatives of the Ministry of Health, of the Secretary of Health of the State of São Paulo, and the following societies:

Brazilian Academy of Neurology – ABN; Brazilian Association for the Study of Obesity – ABESO; Brazilian Federation of Gynecology and Obstetrics Societies – FEBRASGO; Brazilian Society of Internal Medicine - SBCM; Brazilian Society of Diabetes – SBD; Brazilian Society of Endocrinology and Metabolism – SBEM and Brazilian Society of Geriatrics and Gerontology – SBGG.

The Organizing Commission would like to thank the commitment made by all the colleagues who have definitely contributed to the success of this meeting, and who have worked not only during the event but also on the Internet prior to this meeting.

We would like to thank the following laboratories, for their institutional support which has made this meeting possible: AstraZeneca do Brasil Ltda.; Aventis Pharma Ltda.; Bayer S.A.; Biolab Farmacêutica Ltda.; Boehringer Ingelheim do Brasil Quim. e Farm. Ltda.; Farmalab Ind. Químicas e Farmacêuticas Ltda.; Laboratórios Biosintética; Laboratórios Pfizer Ltda.; Libbs Farmacêutica Ltda.; Merck Sharp & Dohme Farmacêutica Ltda.; Novartis Biociências S.A.; Sanofi-Synthélabo Ltda.; Servier do Brasil Ltda.

1

I Consenso Brasileiro de Hipertensão Arterial. Arq Bras Cardiol, 1991; 56(Suppl A): A1–16.

2

II Consenso Brasileiro de Hipertensão Arterial. Arq Bras Cardiol, 1994; 63(4): 333–47.

3

III Consenso Brasileiro de Hipertensão Arterial. Rev Bras Clin Terap, 1998; 24(6): 231–72.

Publication Dates

• Publication in this collection
  22 Apr 2004
• Date of issue
  Mar 2004